Advertisement

Introduction

  • Elize Massard da FonsecaEmail author
Chapter
Part of the SpringerBriefs in Political Science book series (BRIEFSPOLITICAL, volume 26)

Abstract

Brazil is renowned worldwide for its remarkable reforms in pharmaceutical regulation, which have enhanced access to essential medicines while lowering drug costs. As part of these reforms, the Brazilian Congress, with the support of the Ministry of Health (MoH), approved the Generic Drug Act in 1999. A generic drug is a pharmaceutical product that is no longer protected by a patent, and is interchangeable with an innovator drug. A generic drug policy is an intervention to foster market competition, which would prompt price declines and increase access to safe and affordable medicines. In Brazil, pharmacies are the main channel for dispensing medicines to the population and over 80 % of drug expenses are paid for by patients themselves, resulting in pricing being a core determinant of access to medicines. Studies suggest that generic drugs enter the market with an average price of 40 % lower than its patent version, and this difference has increased over time, making medicines more affordable to the Brazilian population and governmental programmes.

Keywords

Generic Drug Market Competition Essential Medicine Brand Loyalty Pharmaceutical Sector 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Center for Public Administration and Government Studies, São Paulo Business SchoolGetulio Vargas FoundationSão PauloBrazil

Personalised recommendations